JP5468899B2 - Ｆａｂｉインヒビターとしてのアクリルアミド誘導体 - Google Patents

Ｆａｂｉインヒビターとしてのアクリルアミド誘導体 Download PDF

Info

Publication number
JP5468899B2
JP5468899B2 JP2009519767A JP2009519767A JP5468899B2 JP 5468899 B2 JP5468899 B2 JP 5468899B2 JP 2009519767 A JP2009519767 A JP 2009519767A JP 2009519767 A JP2009519767 A JP 2009519767A JP 5468899 B2 JP5468899 B2 JP 5468899B2
Authority
JP
Japan
Prior art keywords
methyl
compound
acrylamide
pyrido
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009519767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501474A5 (OSRAM
JP2010501474A (ja
Inventor
ハインツ， ダブリュー． ポールズ，
ジェイラール ラムナウス，
ピーター サンプソン，
アンドラス トロ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affinium Pharmaceuticals Inc
Original Assignee
Affinium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affinium Pharmaceuticals Inc filed Critical Affinium Pharmaceuticals Inc
Publication of JP2010501474A publication Critical patent/JP2010501474A/ja
Publication of JP2010501474A5 publication Critical patent/JP2010501474A5/ja
Application granted granted Critical
Publication of JP5468899B2 publication Critical patent/JP5468899B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Agronomy & Crop Science (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2009519767A 2006-07-20 2007-07-19 Ｆａｂｉインヒビターとしてのアクリルアミド誘導体 Expired - Fee Related JP5468899B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83205806P 2006-07-20 2006-07-20
US60/832,058 2006-07-20
PCT/CA2007/001277 WO2008009122A1 (en) 2006-07-20 2007-07-19 Acrylamide derivatives as fab i inhibitors

Publications (3)

Publication Number Publication Date
JP2010501474A JP2010501474A (ja) 2010-01-21
JP2010501474A5 JP2010501474A5 (OSRAM) 2013-09-12
JP5468899B2 true JP5468899B2 (ja) 2014-04-09

Family

ID=38956481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009519767A Expired - Fee Related JP5468899B2 (ja) 2006-07-20 2007-07-19 Ｆａｂｉインヒビターとしてのアクリルアミド誘導体

Country Status (6)

Country Link
US (2) US8318720B2 (OSRAM)
EP (2) EP2054422B1 (OSRAM)
JP (1) JP5468899B2 (OSRAM)
CA (1) CA2658506C (OSRAM)
IL (1) IL196590A (OSRAM)
WO (1) WO2008009122A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010635A1 (es) 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
AU2002367773A1 (en) 2001-04-06 2003-11-03 Affinium Pharmaceuticals, Inc. Fab i inhibitors
SI1575951T1 (sl) 2002-12-06 2014-10-30 Debiopharm International Sa Forum "Apres-Demain" Heterociklične spojine, postopki za njihovo izdelavo in njihova uporaba v terapiji
US8450307B2 (en) 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
JP5468899B2 (ja) 2006-07-20 2014-04-09 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉインヒビターとしてのアクリルアミド誘導体
EP3255045A1 (en) 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
FR2927331B1 (fr) 2008-02-07 2011-05-20 Centre Nat Rech Scient Nouveaux derives anti-infectieux, leur procede de preparation, compositions pharmaceutiques les contenant et leurs utilisations en therapeutique.
US8394139B2 (en) * 2008-08-29 2013-03-12 Cook Medical Technologies Llc Barbed anchors for wire stent
CN102470127A (zh) 2009-08-19 2012-05-23 埃姆比特生物科学公司 联芳基化合物和其使用方法
CN102812011A (zh) * 2009-11-16 2012-12-05 梅利科技公司 [1,5]-二氮杂环辛间四烯衍生物
JP5816629B2 (ja) 2009-11-18 2015-11-18 ファブ ファーマ エスエーエス 新規の複素環式アクリルアミド及び医薬としてのその使用
CA2802107A1 (en) * 2010-06-11 2011-12-15 Affinium Pharmaceuticals, Inc. Compounds for treatment of bovine mastitis
MY182666A (en) 2010-11-05 2021-01-28 Senomyx Inc Compounds useful as modulators of trpm8
JO3611B1 (ar) 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
ES2881681T3 (es) * 2011-08-10 2021-11-30 Janssen Sciences Ireland Unlimited Co 3,4-Dihidro-1H-[1,8]naftiridinonas sustituidas con piperidinilo antibacterianas
MX360856B (es) 2011-08-10 2018-11-20 Janssen Sciences Ireland Uc 3,4-dihidro-1h-[1,8]naftiridinosas sustituidas con homopiperidinilo antibacterianas.
MY170437A (en) 2012-06-19 2019-07-31 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
WO2014072930A2 (en) * 2012-11-09 2014-05-15 Aurigene Discovery Technologies Limited Fused pyridine derivatives as antibacterial agents
CN108368083B (zh) 2015-08-31 2022-02-01 东亚首希控股股份有限公司 杂芳基化合物及其作为治疗性药物的用途
JP6865743B2 (ja) 2015-10-01 2021-04-28 フィルメニッヒ インコーポレイテッドＦｉｒｍｅｎｉｃｈ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｔｒｐｍ８の活性調節因子として有用な化合物
EA201891620A1 (ru) 2016-02-05 2019-02-28 Денали Терапьютикс Инк. Ингибиторы взаимодействующей с рецептором протеинкиназы 1
PL3419628T3 (pl) 2016-02-26 2021-05-31 Debiopharm International Sa Lek do leczenia zakażeń stopy cukrzycowej
WO2018071343A1 (en) 2016-10-10 2018-04-19 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as mer inhibitors
PL3552017T3 (pl) 2016-12-09 2022-08-08 Denali Therapeutics Inc. Związki użyteczne jako inhibitory RIPK1
SI3880675T1 (sl) 2018-11-12 2025-02-28 Debiopharm International Sa Antibiotične spojine, njihove metode izdelave, farmacevtski sestavki, ki jih vsebujejo, in njihova uporaba
HRP20230437T1 (hr) 2019-02-14 2023-07-07 Debiopharm International S.A. Formulacija afabicina, postupak izrade iste
CN113939306B (zh) 2019-06-14 2024-07-19 德彪药业国际股份公司 用于治疗涉及生物膜的细菌感染的药物及其用途
CN115151541B (zh) 2019-12-19 2024-06-25 德彪药业国际股份公司 新型化合物及其用途
CN112552303B (zh) * 2020-12-14 2021-11-30 承德医学院 嘧啶酮并二氮杂卓类化合物及其盐、其制备方法及医药用途
US20240190872A1 (en) * 2021-03-03 2024-06-13 The Board Of Trustees Of The University Of Illinois Fabi inhibitors for gram-negative pathogens
MX2024008648A (es) 2022-01-12 2024-09-23 Denali Therapeutics Inc Formas cristalinas de (s)-5-bencil-n-(5-metil-4-oxo-2,3,4,5-tetrah idropirido [3,2- b][1,4]oxacepin-3-il)-4h-1,2,4-triazol-3-carboxam ida.
WO2025248051A1 (en) 2024-05-31 2025-12-04 Debiopharm International S.A. Acrylamide derivatives for the treatment of diseases associated with pathogenic bacteria in the gastrointestinal system

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3828068A (en) 1971-05-10 1974-08-06 Tenneco Chem ((substituted indazolyl)-n1-methyl)carbamates
US4154943A (en) 1977-12-29 1979-05-15 University Of Vermont Preparation of vincadifformine
FR2619111B1 (fr) 1987-08-07 1991-01-11 Synthelabo Derives de (piperidinyl-4)methyl-2 tetrahydro-1,2,3,4 9h-pyrido (3,4-b) indole, leur preparation et leur application en therapeutique
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
DE4126662A1 (de) 1991-08-13 1993-02-18 Boehringer Mannheim Gmbh Neue 3,5-di-tert.butyl-4-hydroxyphenyl-derivate, verfahren zu ihrer herstellung und arzneimittel
HU210679B (en) 1991-11-21 1995-06-28 Richter Gedeon Vegyeszet Process for producing new tetrahydro-pyrido/3,4-b/indol derivatives and pharmaceutical compositions containing the same
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5416193A (en) 1993-04-30 1995-05-16 Pfizer Inc. Coupling reagent and method
MA23420A1 (fr) 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
US5614551A (en) 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
BR9508178A (pt) 1994-06-29 1997-11-18 Smithkline Beecham Corp Antagonistas de receptor de vitronectina
US6176842B1 (en) 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US5989832A (en) 1995-04-21 1999-11-23 Microcide Pharmaceuticals, Inc. Method for screening for non-tetracycline efflux pump inhibitors
NZ308518A (en) 1995-05-11 2000-01-28 Biochemie Gmbh Antibacterial cephalosporins
US6057291A (en) 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
TR199801680T2 (xx) 1996-02-29 1999-02-22 Fujisawa Pharmaceutical Co. Ltd. Beta-laktam antibiyotik i�eren tabletler ve �retim y�ntemi.
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6367985B1 (en) 1996-03-12 2002-04-09 Intellectual Property Company Optical connector using large diameter alignment features
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6995254B1 (en) 1996-08-28 2006-02-07 Affinium Pharmaceuticals, Inc. Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I
UA55426C2 (uk) 1996-09-20 2003-04-15 Мейджі Сейка Кайша Лтд. Кристалічний цефдиторен півоксилу і способи його одержання
US6521408B1 (en) 1997-09-25 2003-02-18 National Institute Of Agrobiological Sciences Method for assessing a function of a gene
DE19641437A1 (de) 1996-10-08 1998-04-09 Basf Ag 1,3-Bis-(N-lactamyl)propane und deren pharmazeutische und kosmetische Verwendung
DE19652239A1 (de) 1996-12-16 1998-06-18 Bayer Ag Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
SI9600371B (sl) 1996-12-18 2005-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Etilidenski derivati tricikličnih karbapenemov
JP2001518094A (ja) 1997-03-31 2001-10-09 デュポン ファーマシューティカルズ カンパニー Ｈｉｖプロテアーゼ阻害剤として有用なインダゾール−環式尿素
DE69839261T2 (de) 1997-04-01 2009-03-26 Borody, Thomas Julius, Five Dock Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen
US6406880B1 (en) 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
CN1268135A (zh) 1997-06-23 2000-09-27 吉富制药株式会社 螺杆菌属感染引起的疾病的预防/治疗剂
AUPO758297A0 (en) 1997-06-27 1997-07-24 Rowe, James Baber Control of acidic gut syndrome
US6198000B1 (en) 1997-07-07 2001-03-06 Pfizer Inc. Intermediates useful in the synthesis of quinoline antibiotics
US6313153B1 (en) 1997-07-25 2001-11-06 Tsumura & Co. Compositions and methods for treating nephritis and inhibiting TGF -β related conditions using pyridylacrylamide derivatives
HN1998000106A (es) 1997-08-01 1999-01-08 Pfizer Prod Inc Composiciones parenterales de alatroflaxacino
US5932743A (en) 1997-08-21 1999-08-03 American Home Products Corporation Methods for the solid phase synthesis of substituted indole compounds
GB9717804D0 (en) 1997-08-22 1997-10-29 Zeneca Ltd Chemical compounds
CA2279258A1 (en) 1997-10-31 1999-05-14 Novartis Ag Glyphosate resistant transgenic plants
US6432444B1 (en) 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
JP2001522836A (ja) 1997-11-07 2001-11-20 シェーリング コーポレイション Ｈ３レセプターアンタゴニストとしてのフェニル−アルキル−イミダゾール
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds
GB9725244D0 (en) 1997-11-29 1998-01-28 Zeneca Ltd Chemical compounds
DE19753298A1 (de) 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
HU230295B1 (hu) 1998-01-07 2015-12-28 Meiji Seika Pharma Co., Ltd. Kristálytanilag stabil, amorf, cephalosporin tartalmú készítmény és eljárás előállítására
US6184380B1 (en) 1999-01-25 2001-02-06 Pfizer Inc. Process for preparing naphthyridones and intermediates
US6248343B1 (en) 1998-01-20 2001-06-19 Ethicon, Inc. Therapeutic antimicrobial compositions
PA8466701A1 (es) 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino
US6204279B1 (en) 1998-06-03 2001-03-20 Microcide Pharmaceuticals, Inc. Peptidomimetic efflux pump inhibitors
BRPI9908182C1 (pt) 1998-02-27 2021-05-25 Biora Ab composições de proteína de matriz para cura de feridas
US6350738B1 (en) 1998-03-06 2002-02-26 Brigham Young University Steroid derived antibiotics
US6369049B1 (en) 1998-04-30 2002-04-09 Eli Lilly And Company Treatment of mastitis
DE19820801A1 (de) 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
DE19821039A1 (de) 1998-05-11 1999-11-18 Bayer Ag Verfahren zur Herstellung von (S,S)-Benzyl-2,8-diazabicyclo[4.3.0]nonan
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6428579B1 (en) 1998-07-01 2002-08-06 Brown University Research Foundation Implantable prosthetic devices coated with bioactive molecules
US6423741B1 (en) 1998-07-10 2002-07-23 Council Of Scientific And Industrial Research Anti-microbial composition and method for producing the same
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
KR100412231B1 (ko) 1998-08-04 2003-12-24 다께다 쉐링 플라우 애니멀 헬스 가부시키가이샤 β-락탐 항생물질의 안정화제제
ATE332692T1 (de) 1998-08-21 2006-08-15 Kyorin Seiyaku Kk Wässerige flüssige zubereitungen
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6518487B1 (en) 1998-09-23 2003-02-11 Pioneer Hi-Bred International, Inc. Cyclin D polynucleotides, polypeptides and uses thereof
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
DE19851104C2 (de) 1998-11-06 2003-04-03 Huhtamaki Forchheim Verfahren zum Herstellen eines mehrschichtigen Verbundes
TW526202B (en) 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
US6515113B2 (en) 1999-02-18 2003-02-04 The Regents Of The University Of California Phthalamide lanthanide complexes for use as luminescent markers
US6235728B1 (en) 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
WO2000052035A1 (en) 1999-03-03 2000-09-08 Princeton University Bacterial transglycosylases: assays for monitoring the activity using lipid ii substrate analogs and methods for discovering new antibiotics
US6495161B1 (en) 1999-03-09 2002-12-17 Vivorx, Inc. Cytoprotective biocompatible containment systems for biologically active materials and methods of making same
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6224579B1 (en) 1999-03-31 2001-05-01 The Trustees Of Columbia University In The City Of New York Triclosan and silver compound containing medical devices
CA2367173A1 (en) 1999-04-08 2000-10-12 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
US6290946B1 (en) 1999-05-13 2001-09-18 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
US6514535B2 (en) 1999-05-21 2003-02-04 Noveon Ip Holdings Corp. Bioadhesive hydrogels with functionalized degradable crosslinks
AR024077A1 (es) 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
AR024158A1 (es) 1999-06-01 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
CO5180605A1 (es) 1999-06-23 2002-07-30 Smithkline Beecham Corp Compuestos de indol
CA2282066C (en) 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6346391B1 (en) 1999-07-22 2002-02-12 Trustees Of Tufts College Methods of reducing microbial resistance to drugs
ATE270558T1 (de) 1999-08-26 2004-07-15 Ganeden Biotech Inc Verwendung von emu-öl als träger für fungizide, antibakterielle und antivirale arzneien
US6221859B1 (en) 1999-08-27 2001-04-24 Merck & Co., Inc. Carbapenem antibacterial compositions and methods of the treatment
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
US6428444B1 (en) * 1999-09-06 2002-08-06 Toyota Jidosha Kabushiki Kaisha Apparatus for controlling a vehicle and a method of controlling the vehicle
CA2383570C (en) 1999-09-11 2008-08-12 The Procter & Gamble Company Pourable liquid vehicles
WO2001021175A1 (fr) 1999-09-17 2001-03-29 Suntory Limited Compositions médicinales antibactériennes
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
WO2001026654A1 (en) 1999-10-08 2001-04-19 Smithkline Beecham Corporation Fab i inhibitors
PE20010635A1 (es) 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
AU7866300A (en) 1999-10-08 2001-04-23 Smithkline Beecham Corporation Fab i inhibitors
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6503908B1 (en) 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
ES2225237T3 (es) 1999-10-19 2005-03-16 Sato Pharmaceutical Co. Ltd. Agentes antimicrobianos de tipo 4-oxoquinolizina que tienen cadenas principales de 2-piridona como estructura parcial.
US6951729B1 (en) 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
CN1188111C (zh) 1999-10-29 2005-02-09 耐科塔医药公司 分散性得到改进的干粉组合物
US6531291B1 (en) 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
US6514986B2 (en) 2000-11-22 2003-02-04 Wockhardt Limited Chiral fluoroquinolone arginine salt forms
US6656703B1 (en) 1999-12-29 2003-12-02 Millennium Pharamaceuticals, Inc. High throughput screen for inhibitors of fatty acid biosynthesis in bacteria
US6372752B1 (en) 2000-02-07 2002-04-16 Genzyme Corporation Inha inhibitors and methods of use thereof
ES2179729B1 (es) 2000-03-23 2003-12-16 Dreiman Lab Farmaceuticos S A Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
AU2000255628A1 (en) 2000-03-28 2001-10-08 Council Of Scientific And Industrial Research Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
CN1438981A (zh) 2000-04-21 2003-08-27 罗迪亚/奇莱克斯公司 制备r－1－(芳氧基)丙－2－醇的方法
US6503953B2 (en) 2000-07-26 2003-01-07 Atopic Pty Ltd. Methods for treating atopic disorders
DE10037029A1 (de) 2000-07-27 2002-02-28 Kugelstrahlzentrum Aachen Gmbh Verfahren und Vorrichtung zum Umformen von Strukturbauteilen
US6288239B1 (en) 2000-09-19 2001-09-11 Board Of Trustees Operating Michigan State University 5-trityloxymethyl-oxazolidinones and process for the preparation thereof
US6821746B2 (en) 2000-10-06 2004-11-23 Affinium Pharmaceuticals, Inc. Methods of screening for FabK antagonists and agonists
US7048926B2 (en) 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
HUP0400651A2 (hu) 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
US20020107266A1 (en) 2000-12-12 2002-08-08 Marguerita Lim-Wilby Compounds, compositions and methods for treatment of parasitic infections
US6388070B1 (en) 2001-01-05 2002-05-14 Orchid Chemicals & Pharmaceuticals Ltd. Thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds
US6495158B1 (en) 2001-01-19 2002-12-17 Lec Tec Corporation Acne patch
PA8539401A1 (es) 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
AU2002367773A1 (en) 2001-04-06 2003-11-03 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US6503906B1 (en) 2002-02-21 2003-01-07 Ren-Jin Lee Method for optimizing ciprofloxacin treatment of anthrax-exposed patients according to the patient's characteristics
CA2481178A1 (en) 2002-04-02 2003-10-23 Tatsuhiro Obata Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative
AU2003250475A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
SI1575951T1 (sl) 2002-12-06 2014-10-30 Debiopharm International Sa Forum "Apres-Demain" Heterociklične spojine, postopki za njihovo izdelavo in njihova uporaba v terapiji
ATE409485T1 (de) 2003-03-17 2008-10-15 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US8450307B2 (en) 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
JP2009518399A (ja) * 2005-12-05 2009-05-07 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉ阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物
JP5468899B2 (ja) 2006-07-20 2014-04-09 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉインヒビターとしてのアクリルアミド誘導体
US8163902B2 (en) 2006-11-21 2012-04-24 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP3255045A1 (en) 2007-02-16 2017-12-13 Debiopharm International SA Salts, prodrugs and polymorphs of fab i inhibitors
WO2009003136A1 (en) 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
WO2010117920A1 (en) 2009-04-08 2010-10-14 C&D Zodiac, Inc. Vehicle seat tubing having variable wall thickness
UA108077C2 (xx) 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
JP5816629B2 (ja) 2009-11-18 2015-11-18 ファブ ファーマ エスエーエス 新規の複素環式アクリルアミド及び医薬としてのその使用
CA2802107A1 (en) 2010-06-11 2011-12-15 Affinium Pharmaceuticals, Inc. Compounds for treatment of bovine mastitis
CN102675311A (zh) 2011-06-14 2012-09-19 苏春华 一种氟代丙烯酰胺的衍生物
JP6013846B2 (ja) 2011-10-06 2016-10-25 リコー電子デバイス株式会社 スイッチングレギュレータ及び電子機器
US8975502B1 (en) 2012-05-15 2015-03-10 Rodulfo Delgado Guitar with body-mounted tuning system
MY170437A (en) 2012-06-19 2019-07-31 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
US8973902B2 (en) 2012-12-21 2015-03-10 Comeup Industries Inc. Power winch horizontal-pull clutch device

Also Published As

Publication number Publication date
EP2687533A3 (en) 2014-04-16
IL196590A (en) 2017-03-30
US20130237523A1 (en) 2013-09-12
EP2054422B1 (en) 2017-06-14
EP2054422A1 (en) 2009-05-06
CA2658506C (en) 2016-01-26
US8895545B2 (en) 2014-11-25
WO2008009122A1 (en) 2008-01-24
EP2687533B1 (en) 2017-07-19
CA2658506A1 (en) 2008-01-24
JP2010501474A (ja) 2010-01-21
US8318720B2 (en) 2012-11-27
US20100130470A1 (en) 2010-05-27
EP2687533A2 (en) 2014-01-22
EP2054422A4 (en) 2012-10-03
IL196590A0 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
JP5468899B2 (ja) Ｆａｂｉインヒビターとしてのアクリルアミド誘導体
JP5087406B2 (ja) 治療薬ならびにその製造方法および使用方法
JP2012006927A (ja) ヘテロ環化合物、その製造方法および治療におけるその使用
JP4880448B2 (ja) 複数の抗生物質を含む組成物、及びそれを用いる方法
JP2009518399A (ja) Ｆａｂｉ阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物
CN101415701A (zh) 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂
EA043636B1 (ru) АНТИБАКТЕРИАЛЬНЫЕ 3,4-ДИГИДРО-1Н-[1,8]НАФТИРИДИНОНЫ, ЗАМЕЩЕННЫЕ ЦИКЛОПЕНТА[с]ПИРРОЛОМ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130415

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130515

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130617

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130716

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130716

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140130

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees